ClinicalTrials.gov
public full text
Public Domain
Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma
The primary purpose of the study is to determine the proportion of patients without progression at 6-months in patients with unresectable Stage III or Stage IV melanoma who are taking RTA 402.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Biological Therapy in Treating Patients With Metastatic Melanoma#329503
- French Clinical Datbase of Melanoma Patients (RIC-Mel)#454031
- Phase I/II Study of Chemo-Immunotherapy Combination in Melanoma Patients#18585
- Use of 852A in Metastatic Cutaneous Melanoma.#1102354
- Real-world treatment patterns in stage III and IV melanoma patients: insights from a global multi-center chart review study.#437037
Record · ID 842460
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive